InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,010.60
(
0.00%
)
US TECH 100
16,808.00
(
0.33%
)
Dow Jones
38,239.98
(
0.00%
)
Brent Oil
85.42
(
-1.15%
)
Bitcoin
66,154.70
(
-1.05%
)
Post# of 38376
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

bucks2pennies

Send PM Follow Ignore
Followers 176
Posts 16204
Boards Moderated 0
Alias Born 11/10/2008

bucks2pennies

Member Level

Re: None

Friday, 10/02/2015 4:04:35 PM

Friday, October 02, 2015 4:04:35 PM

Post# of 38376
ENTB. "On September 28, 2015 Zander Therapeutics, Inc. ("Zander") executed an agreement ("Agreement') with Regen BioPharma, Inc. ( "Regen") whereby Zander shall cause to be issued to Regen 8,000,000 common shares of Entest Biomedical Inc. ("Shares") in full satisfaction of Zander's obligation to pay to Regen a one-time, non-refundable, upfront payment of $100,000 as a license initiation."

That is still dilution! No mention of restriction on these shares. Comes out to .0125 per share.

Not the news I wanted to hear.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up